Mutabilis Raises 8 Million Euros
Paris - French drug discovery company Mutabilis S.A. closed an Euro8 million series B financing in mid-June with Auriga Partners as lead investor. The capital will provide sufficient financing to continue drug discovery activities until 2007, according to the company. Mutabilis develops new anti-infective molecules, that target virulence determinants on the surface of pathogenic bacteria which are multiresistent to current antibiotics.
“The new financing will allow Mutabilis to develop new chemical entities and to demonstrate that these molecules work in animals. By targeting just the bacteria responsible for an infection while leaving unharmed the intestinal flora and bacteria living in natural sites, Mutabilis' technology aims at allowing widespread use of anti-infective agents in situations where physicians today cannot use antibiotics because due the development of bacterial resistance”, explains Stéphane Huguet, CEO of Mutabilis. Clinical trials are expected to start in 2006.